Atomoxetine in Patients With Tourette's Syndrome
Reason given: experimental treatment (Atomoxetine) not available
Key facts
- Phase
- Phase 2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Poitiers University Hospital
- Trial code
- NCT04354103
- Record updated
- 23 January 2024
- Original description
The purpose of this pilot study is to evaluate the effects of Atomoxetine, a selective noradrenaline reuptake inhibitor, on impulsivity in patients with Tourette's syndrome.Read full original descriptionShow less
A Pilot Study to Evaluate the Effects of Atomoxetine on Impulsivity in Patients With Tourette's Syndrome
The purpose of this pilot study is to evaluate the effects of Atomoxetine, a selective noradrenaline reuptake inhibitor, on impulsivity in patients with Tourette's syndrome.
Inclusion: High impulsive patients, aged 10-35 years old, diagnosed for Tourette's syndrome as defined by the DSM-IV, never treated by Atomoxetine; The use of effective contraception or abstinence for subjects of reproductive age; Written informed consent.
Exclusion: Patients with mental retardation, psychotic disorders as schizophrenia, autism spectrum disorders, chronic tics which do not respond to Tourette's syndrome criteria; Allergy to one of the constituents; Severe cardiovascular or cerebrovascular diseases, Pheochromocytoma, uncontrolled hyperthyroidism, closed angle glaucoma; Actual severe depression; IMAO treatment discontinued less than 2 months or contra-indicated associated treatment.